Products

What will AGI do for Bezafibrate?

This classification denotes an anti-lipidemic agent with the molecular formula C19H20ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y9449Q51XH, chemically known as propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl- but generally known as bezafibrate, which bears US NIH Compound Identifier 39042. European Medicines Agency schedules Bezafibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05810MIG. The term BEZAFIBRATE is an International Non-Proprietary Name. World Health Organization schedules bezafibrate in its Anatomical Therapeutic Chemical (ATC) Classification. BEZAFIBRATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bezafibrate under HS 29242995 and SITC 51479. As of Q4 2014, BEZAFIBRATE remains the US FDA Preferred Term for this commodity. Bezafibrate bears US NLM identifiers UMLS ID C0005330 and NCI Concept Code C87449. SMILES: Clc1ccc(C(=O)NCCc2ccc(OC(C)(C)C(=O)O)cc2)cc1.

How AGI delivers it

Four ways AGI delivers for Bezafibrate

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bezafibrate, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bezafibrate, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bezafibrate connects

measured by

  • Assay Puritymodel
  • Chromatographic Impurity Profilemodel
  • Dissolution Ratemodel
  • Particle Size Distributionmodel
  • Residual Solventmodel